Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 3, 1998, Pages 1317-1326

  Bednar, Rodney A ^a   Gaul, S Lee ^a   Hamill, Terence G ^a   Egbertson, Melissa S ^a   Shafer, Jules A ^a   Hartman, George D ^a   Gould, Robert J ^a   Bednar, Bohumil ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINYLASPARAGINYL 5,5 DIMETHYLTHIOPROLYL 4 AMINOMETHYLPHENYLALANYLGLYCYLASPARTYLCYSTEINE; ARGINYLGLYCYLASPARTIC ACID; CYCLO(DEXTRO 2 AMINOBUTYRYL 2 N METHYLARGINYLGLYCYLASPARTYL 3 AMINOMETHYLBENZOIC ACID) METHANESULFONATE; DANSYL CHLORIDE; ECHISTATIN; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPTAPEPTIDE; L 692884; L 734217; L 736622; LAMIFIBAN; N [(4 METHYLPHENYL)SULFONYL] 3 [[[5,6,7,8 TETRAHYDRO 4 OXO 5 [2 (4 PIPERIDINYL)ETHYL] 4H PYRAZOLO[1,5 A][1,4]DIAZEPIN 2 YL]CARBONYL]AMINO]ALANINE; RO 435054; THROMBIN; THROMBOCYTE RECEPTOR; TIROFIBAN; UNCLASSIFIED DRUG; YTTRIUM SILICATE Y 90;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOG; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION;

AZEPINES; BINDING, COMPETITIVE; BLOOD PLATELETS; FIBRINOLYTIC AGENTS; HUMANS; OLIGOPEPTIDES; PEPTIDES; PEPTIDES, CYCLIC; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SULFONAMIDES; THIAZOLIDINES;

EID: 0031837758     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Abrams C and Shattil SJ (1991) Immunological detection of activated platelets in clinical disorders. Thromb Haemost 65:467-473.
2. Abrams CS, Ellison N, Budzynski AZ and Shattil SJ (1990) Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 75:128-138.
3. Alig L, Edenhofer A, Hadvary P, Hurzeler M, Knopp D, Muller M, Steiner B, Trzeciak A and Weller T (1992) Low molecular weight, non-peptide fibrinogen receptor antagonists. J Med Chem 35:4393-4407.
4. Bednar B, Bednar RA, Cook JJ, Bollag DM, Chang CT, Gaul SL, McQueney PA, Egbertson MS, Hartman GD, Holahan MA, Lynch JJ and Gould RJ (1996) Drug-dependent antibodies against GP IIb/IIIa induced thrombocytopenia. Circulation 94:571.
5. Bednar B, Cunningham ME, McQueney PA, Egbertson MS, Askew BC, Bednar RA, Hartman GD and Gould RJ (1997) Flow cytometric measurement of kinetic and equilibrium binding parameters of arginine-glycine-aspartic acid ligands in binding of glycoprotein IIb/IIIa on platelets. Cytometry 28:58-65.
6. Bennett JS (1991) Integrin structure and function in hemostasis and thrombosis. Ann NY Acad Sci 614:214-228.
7. Bosworth N and Towers P (1989) Scintillation proximity assay. Nature 341:167-168.
8. Carrell NA, Fitzgerald LA, Steiner B, Erickson HP and Phillips DR (1985) Structure of human platelet membrane glycoprotein IIb and IIIa as determined by electron microscopy. J Biol Chem 260:1743-1749.
9. Coller BS, Folts JD, Scudder LE and Smith SR (1986) Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 68:783-786.
10. Coller BS (1992) Antiplatelet agents in the prevention and therapy of thrombosis. Annu Rev Med 43:171-180.
11. Coller BS (1995) The role of platelets in arterial thrombosis and the rationale for blockade of platelet GP IIb/IIIa receptors as antithrombotic therapy. Eur Heart J 16: suppl L,11-15.
12. Coller BS (1997) Platelet GP IIb/IIIa antagonists: The first anti-integrin receptor therapeutics. J Clin Invest 99:1467-1471.
13. Cook N, Sutton J and Takeuchi K (1992) SPA: A revolutionary new technique for drug screening. Pharmaceutical Manufacturing International, Sterling Publications Limited, 49-52.
14. Cook JJ, Holahan MA, Lyle EA, Ramjit DR, Sitko GR, Stranieri MT, Stupienski RF, Wallace AA, Hand EL, Gehret JR, Kothstein T, Drag MD, McCormick GY, Perkins JJ, Ihle NC, Duggan ME, Hartman, GD, Gould RJ and Lynch JJ (1996) Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. J Pharmacol Exp Ther 278:62-73.
15. Cook JJ, Glass JD, Sitko GR, Holahan MA, Stupienski RF, Wallace AA, Stump GL, Hand EL, Askew BC, Hartman GD, Gould RJ, Lynch JJ (1997) Nonpeptide glycoprotein IIb/IIIa inhibitors. 14. Oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury. Circulation 96:949-958.
16. Duggan ME, Naylor-Olsen AM, Perkins JJ, Anderson PS, Chang CTC, Cook JJ, Gould RJ, Ihle NC, Hartman GD, Lynch JJ, Lynch RJ, Manno PD, Schaffer LW and Smith RL (1995) Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. J Med Chem 38:3332-3341.
17. Egbertson MS, Bednar B, Bednar RA, Hartman GD, Gould RJ, Lynch RJ, Vassallo LM and Young SD (1996) Non-peptide glycoprotein IIb/IIIa inhibitors. 9. Centrally constrained alpha-sulfonamides are useful tools for exploring platelet receptor function. Bioorg Med Chem Lett 6:1415-1420.
18. Egbertson MS, Chang CTC, Duggan ME, Gould RJ, Halczenko W, Hartman GD, Laswell WL, Lynch JJ, Lynch RJ, Manno PM, Naylor AM, Prugh JD, Ramjit DR, Sitko GR, Smith RS, Turchi LM and Zhang G. J (1994a) Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J Med Chem 37:2537-2551.
19. Egbertson MS, Naylor AM, Hartman GD, Cook JJ, Gould RJ, Holahan MA, Lynch JJ, Lynch RJ, Stranieri MT and Vassallo LM (1994b) Non-peptide fibrinogen receptor antagonists. 3. Design and discovery of a centrally constrained inhibitor. Bioorg Med Chem Lett 4:1835-1840.
20. Epic Investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956-961.
21. Fitzgerald DJ, Roy L, Catella F and FitzGerald GA (1986) Platelet activation in unstable coronary disease. N Engl J Med 315:983-989.
22. Fitzgerald DJ, Wright F and FitzGerald GA (1989) Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo. Circ Res 65:83-94.
23. Gan ZR, Gould RJ, Jacobs JW, Friedman PA and Polokoff MA (1988) Echistatin: A potent platelet aggregation inhibitor from the venom of the viper, Echis Carinatus. J Biol Chem 263:19827-19832.
24. George JN and Shattil SJ (1991) The clinical importance of acquired abnormalities of platelet function. N Engl J Med 324:27-39.
25. 3 as an antithrombotic target. Perspect Drug Discov Des 1:537-548.
26. Hamm CW, Lorenz RL, Bleifeld W, Kupper W, Wober W and Weber PC (1987) Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 10:998-1004.
27. Harker LA (1987) Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol 60:20B-28B.
28. Hartman GD, Egbertson MS, Halczenko W, Laswell WL, Duggan ME, Smith RL, Naylor AM, Manno PD, Lynch RJ, Zhang G, Chang CTC and Gould RJ (1992) Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J Med Chem 35:4640-4642.
29. Hulme EC and Birdsall NJM (1992) Strategy and tactics in receptor-binding studies, in Receptor-Ligand Interactions (Hulme EC, ed) pp 63-176, Oxford University Press, Oxford.
30. Hung TF and Niewiarowski S (1994) Disintegrins: The naturally-occurring antagonists of platelet fibrinogen receptor. J Toxicol Toxin Rev 13:253-273.
31. Jordan RE, Wagner CL, Mascelli MA, Treacy G, Nedelman MA, Woody JN, Weisman HF and Coller BS (1996) Preclinical development of c7E3 Fab; a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GP IIb/IIIa receptors with observations of the immunogenicity of c7E3 Fab in humans, in Adhesion Receptors as Therapeutic Targets (Horton MA, ed) pp 281-305, CRC Press, New York, NY.
32. Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V and Sax FL (1996) Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 27:536-542.
33. Kieffer N and Phillips DR (1990) Platelet membrane glycoproteins: Functions in cellular interactions. Annu Rev Cell Biol 6:329-357.
34. Kouns WC, Hadvary P, Haering P and Steiner B (1992) Conformational modulation of purified Glycoprotein (GP) IIb-IIIa allows proteolytic generation of active fragments from either active or inactive GP IIb-IIIa. J Biol Chem 267:18844-18851.
35. 3. J Biol Chem 271:20315-20321.
36. 3 receptor on resting and activated human platelets. Biochem J 301:429-436.
37. Phillips DR, Charo IF, Parise LV and Fitzgerald LA (1988) The platelet membrane glycoprotein IIb-IIIa complex. Blood 71:831-843.
38. Plow EF and Ginsberg MH (1989) Cellular adhesion: GP IIb/IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 9:117-156.
39. Rasmanis G, Vesterqvist O, Green K, Edhag O and Henriksson P (1992) Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction. Br Heart J 68:374-376.
40. Scharf RE, Tomer A, Marzec UM, Teirstein PS, Ruggeri ZM and Harker LA (1992) Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arterioscler Thromb 12:1475-1487.
41. Stein B, Fuster V, Israel DH, Cohen M, Badimon L, Badimon JJ and Chesebro JH (1989) Platelet inhibitor agents in cardiovascular disease: An update. J Am Coll Cardiol 14:813-836.
42. Takeuchi K (1992) Scintillation proximity assay. Lab Pract 40:69-71.
43. Tcheng JE (1996) Platelet integrin glycoprotein IIb/IIIa inhibitors: Opportunities and challenges. J Invasive Cardiol 8:8B-14B.
44. Theroux P, White H, David D, Van de Werf F, Nienaber CA, Charbonnier B, Erhardt L, Gill J, Hillis WS, Jennings G, Tan, L-B, Deschenes N, Fitzpatrick V and Sax FL (1994) A heparin-controlled study of MK-383 in unstable angina. Circulation 90:I-231.